オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - codeine phosphate hemihydrate, quantity: 9.6 mg; paracetamol, quantity: 499.9995 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; quinoline yellow aluminium lake; povidone; croscarmellose sodium; pregelatinised maize starch; maize starch; stearic acid; crospovidone - for the temporary relief of acute moderate pain in patients over the age of 12 years.

マルタ - 英語 - Malta Medicines Authority

mint health ltd 3/4, cantrija complex, triq it-targa, il-maghtab naxxar. nxr6613, malta - codeine phosphate - tablet - codeine phosphate 30 milligram(s) - cough and cold preparations

マルタ - 英語 - Malta Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - codeine phosphate - tablet - codeine phosphate 30 mg - cough and cold preparations

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - paracetamol; codeine phosphate hemihydrate - tablet - codeine and paracetamol

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

pharmpak, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain. codeine-containing products are contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. this product should not be administered to patients who have previously exhibited hypersensitivity to codeine or acetaminophen. controlled substance: acetaminophen and codeine phosphate tablets are classified as a schedule iii controlled substance.   abuse and dependence: codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. psychological dependence, physical dependence, and tolerance may develop upon repeated administration, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine - unii:q830pw7520) - codeine sulfate 60 mg - codeine sulfate is an opioid analgesic indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate. codeine sulfate is contraindicated in patients with known hypersensitivity to codeine or any components of the product. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. codeine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. codeine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. codeine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. enter section text here codeine sulfate is an opioid agonist and is a schedule ii controlled substance. codeine sulfate can be abused and is subject to criminal diversion.  drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. drug addiction is

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - codeine phosphate hemihydrate; paracetamol - effervescent tablet - 500/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mikart, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (codeine - unii:q830pw7520) - tablet - 712.8 mg - acetaminophen, caffeine and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or in any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance ma

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - codeine phosphate - oral tablet - 30mg

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - codeine phosphate hemihydrate 15mg;   - tablet - 15 mg - active: codeine phosphate hemihydrate 15mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water   sodium starch glycolate